Pharvaris (NASDAQ:PHVS) Shares Down 6.9% – Time to Sell?

Pharvaris N.V. (NASDAQ:PHVS) shares traded down 6.9% on Tuesday . The stock traded as low as $25.34 and last traded at $25.21. 163,964 shares changed hands during trading, an increase of 4% from the average session volume of 157,212 shares. The stock had previously closed at $27.07.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PHVS. Wedbush upped their price objective on Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Morgan Stanley boosted their target price on Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Wall Street Zen downgraded Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Citigroup restated a “market outperform” rating on shares of Pharvaris in a report on Wednesday, November 19th. Finally, Bank of America increased their price target on shares of Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.56.

Pharvaris Stock Down 6.9%

The business’s fifty day moving average price is $24.11 and its 200 day moving average price is $22.29. The firm has a market capitalization of $1.32 billion, a PE ratio of -7.86 and a beta of -2.80.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. As a group, sell-side analysts forecast that Pharvaris N.V. will post -2.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. General Atlantic L.P. raised its stake in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares during the period. Foresite Capital Management IV LLC lifted its holdings in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares during the last quarter. venBio Partners LLC raised its position in shares of Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares during the period. Deerfield Management Company L.P. raised its position in shares of Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares during the period. Finally, Commodore Capital LP boosted its position in shares of Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after purchasing an additional 507,043 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.